دورية أكاديمية
Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
| العنوان: | Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership. |
|---|---|
| المؤلفون: | Piper Vallillo AJ; Division of Hematology and Oncology, Lahey Hospital and Medical Center & Tufts University School of Medicine; Boston, MA., Viray H; Division of Medical Oncology, Beth Israel Deaconess Medical Center & Harvard Medical School; Boston, MA., Feldman J; Co-Founder, EGFR Resisters; Deerfield, MA., Rangachari D; Division of Medical Oncology, Beth Israel Deaconess Medical Center & Harvard Medical School; Boston, MA. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 10; Vol. 42 (11), pp. 1215-1221. Date of Electronic Publication: 2024 Feb 27. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics, Humans ; Quality of Life ; ErbB Receptors/genetics ; Medical Oncology |
| مستخلص: | The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice. Patients with epidermal growth factor receptor ( EGFR )-mutated advanced non-small-cell lung cancer represent a distinct subgroup of individuals who can experience initially tolerable and durable effects with first-line EGFR-directed tyrosine kinase inhibitors. Unfortunately, acquired treatment resistance and cancer progression within the CNS are inevitable during the disease course and present a challenging transition in the care continuum. Next-line therapies generally require combinations of drugs and afford nuanced differences in clinical outcomes relative to the treatment experience, toxicity profile, and quality of life. Therapeutic stratification and modulation thus require further personalization and partnership with patients to identify key clinical, molecular, and human-specific factors to best guide optimal care. |
| المشرفين على المادة: | EC 2.7.10.1 (ErbB Receptors) |
| تواريخ الأحداث: | Date Created: 20240227 Date Completed: 20240408 Latest Revision: 20240408 |
| رمز التحديث: | 20240408 |
| DOI: | 10.1200/JCO.23.02417 |
| PMID: | 38412397 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.23.02417 |